Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors

European Journal of Clinical Pharmacology

Volumn 54, Issue 9-10, 1998, Pages 741-747

  Gass, R J A ^a   Gal, J ^a   Fogle, P W ^a   Detmar Hanna, D ^a   Gerber, John G ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cortisol hydroxylation; CYP3A4; Dapsone N hydroxylation

Indexed keywords

DAPSONE; HYDROCORTISONE; INDINAVIR; RITONAVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG DETERMINATION; DRUG EFFECT; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS INHIBITION;

ADULT; ANTI-INFLAMMATORY AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; HYDROCORTISONE; HYDROXYLATION; INDINAVIR; KINETICS; LEPROSTATIC AGENTS; MALE; MIXED FUNCTION OXYGENASES; PREDICTIVE VALUE OF TESTS; RITONAVIR;

EID: 0032443842     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050545     Document Type: Article

References (51)

1. Mathez Z, De Truchis, Gorin I et al (1996) Ritonavir, AZT. DDC as a triple combination in AIDS patients. In: Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infection. January 28-February 1, 1996, Washington DC, Abstract 285
2. Cameron W, Heath-Chiozzi M, Kravcik S et al (1996) Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections, January 28-February 1, 1996, Washington DC, Abstract LB6A
3. Massari F, Conant M, Mellors J et al (1996) A phase II open-label, randomized study of the triple combination of indinavir, zidovudine, and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. In: Program and Abstracts of Third Conference on Retroviruses and Opportunistic Infection, January 28-February 1, 1996, Washington DC, Abstract 200
4. Gulick RM, Mellors J, Havlir D et al (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739
5. 3. In: Program and Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, January 22 26, 1997, Washington DC, Abstract LB7
6. ™ (nelfinavir mesylate, NVF) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with D4T or AZT/3TC. In: Program and Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, January 22 26, 1997, Washington DC, Abstract 370
7. Hammer SM, Squires KE, Hughes MD et al (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less. N Engl J Med 337: 725-733
8. Kohl NE, Emini E, Schleif WA et al (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85: 4686-4690
9. Tang J, Lin Y, Co E, Hartsuck JA, Lin X (1992) Understanding protease can be translated into effective therapy against AIDS. Scand J Clin Invest 52: 127-135
10. Denissen JF, Grabowski BA, Johnson MK et al (1997) Metabolism and disposition of the HIV-1 protease inhibitior ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 25: 489-501
11. Balani SK, Woolf EJ, Hoagland VL et al (1996) Disposition of indinavir, a potent HIV-1 protease inhibitor after an oral dose in humans. Drug Metab Dispos 24: 1389-1394
12. Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44: 190-194
13. Woolley J, Studenberg S, Boehlert C, Bowers G, Sinhababu A, Adams P (1997) Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 28 October 1, 1997; Toronto, Canada, Abstract A-60
14. Kumar GN, Rodrigues AD, Buko AM, Denissen JE (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277: 423-431
15. Norbeck D, Kumar G, Marsh K et al (1995) Ritonavir and saquinavir: potential for two-dimensional synergy between protease inhibitors. In: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, September 17 20, 1995, San Fransisco, Calif., Abstract LB7
16. Kempf D, Marsh K, Denissen J et al (1996) Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450. In: Programs and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections, January 28 February 1, 1996, Washington DC, Abstract 143
17. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH (1996) Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 24: 307-314
18. Webber S, Shelly B, Wu E, Zorbas M (1996) In vitro and in vivo metabolism and cytochrome P450 induction studies with the HIV-1 protease inhibitor, Viracept (AG1343). In: Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections, January 28 February 1, 1996, Washington DC, Abstract 144
19. Polk RE, Israel DS, Patron R et al (1997) Effects of the HIV-1 protease inhibitor, 141W94, and rifampin, and rifabutin on P450 3A4 activity as measured by erythromycin breath test. In: Program and Abstracts of 35th Meeting of the Infectious Diseases Society of America. September 13 16, 1997, San Francisco, Calif., Abstract 236
20. Israili ZH, Cucinell SA, Vaught J et al (1973) Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites. J Pharmacol Exp Ther 187: 138-151
21. Gelber R, Peters JH, Gordon GR, Glazko AJ, Levy L (1971) The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther 12: 225-238
22. Fleming CM, Branch RA, Wilkinson GR, Guengrich FP (1992) Human liver microsomal N-hydroxylation of dapsone by cytochrome P-450 3A4. Mol Pharmacol 41: 975-980
23. May GD, Porter J, Wilkinson GR, Branch RA (1994) Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity in a while population. Clin Pharmacol Ther 55: 492-500
24. May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA (1990) The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 48: 619-627
25. May DG, Arns PA, Richards WO et al (1992) The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 51: 689-700
26. Canalis E, Reardon GE, Caldarella AM (1982) A more specific liquid-chromatographic method for free cortisol in urine. Clin Chem 28: 2418-2420
27. Ged C, Rouillon JM, Pichard L et al (1989) The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28: 373-387
28. Foster BL, Dunn R (1974) Single-antibody technique for radioimmunoassay of cortisol in unextracted serum or plasma. Clin Chem 20: 365-368
29. Parker DR, Wang M-C, Gitterman ML, Walsh PR (1979) A solid-phase, non-chromatographic radioimmunoassay for urinary free cortisol. Clin Chem 25: 1152
30. Zhiri A, Wellman-Bednawska M, Siest G (1986) ELISA of 6β-hydroxycortisol in human urine: diurnal variations and effects of antiepileptic therapy. Clin Chim Acta 157: 267-276
31. Cato A, Cavanaugh JH, Shi H et al. (1996) Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. In: Programs and Abstracts of the XI International Conference on AIDS. July 7 12, 1996, Vancouver, British Columbia, Abstract MoB, 1199
32. Ouellet D, Hsu A, Granneman GR et al (1996) Assessment of pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 59[2]: 143 Abstract PI-58
33. Cameron W, Sun E, Markowitz M et al (1996) Combination use of ritonavir and saquinavir in HIV infected patients: preliminary safety and activity data. In: Program and Abstracts of the 11th International Conference on AIDS, July 7 12 1996, Vancouver, British Columbia, Abstract ThB, 934
34. Eagling VA, Back DJ, Barry MC, (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44: 190 194
35. The Indinavir (MK-639) Pharmacokinetic Study Group (1996) Indinavir (MK-639) drug interaction studies. In: Program and Abstracts of the 11th International Conference of AIDS, July 7 12 1996, Vancouver, British Columbia, Abstract MoB174
36. Everson RE, Weidle PJ, Perdue BE, Bozek PS (1997) Evaluation of drug interactions with indinavir. In: Program and Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. January 22 26, 1997, Washington DC, Abstract 611
37. Kinirons MT, O'Shea D, Downing TE et al (1993) Absence of correlation's among three in vivo putative probes of human cytochrome P450 3A activity in young healthy men. Clin Pharmacol Ther 54: 621-629
38. Hunt CM, Watkins PB, Saenger P et al (1992) Heterogeneity of CYP 3A isoforms metabolizing erythromyein and cortisol. Clin Pharmacol Ther 51: 18-23
39. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJ (1996) Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP 3A activity in patients with rheumatoid arthritis receiving cyclosporin. Clin Pharmacol Ther 59: 47-51
40. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171-184
41. Watkins PB, Wrighton SA, Scheutz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80: 1029-1036
42. Murray GI, Barnes TS, Sewell HF et al (1988) The immunocytochemical localization and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 25: 465-475
43. Kolars JC, Schmiedlin-Ren P, Scheutz JD, Fang C, Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90: 1871-1878
44. Gill HJ, Tingle MD, Park K (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of drug toxicity. Br J Pharmacol 40: 531-538
45. Mitra AK, Thummel KE, Kalhorn TF et al (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 58: 556-566
46. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM (1986) Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11: 299-315
47. Ouellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Grannerman GR (1996) Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. In: Programs and Abstracts of the 11th International Conference on AIDS, July 7-12, 1996, Vancouver, British Columbia, Abstract Mo.B. 1198
48. Hsu A, Granneman GR, Witt G, Cavanaughl JL, Leonard J (1996) Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. In: Programs and Abstracts of the 11th International Conference on AIDS, July 7-12, 1996, Vancouver, British Columbia, Abstract Mo.B. 1200
49. Frye RF, Bertz RJ, Granneman GR et al (1998) The effect of ritonavir on CYPIA2, 2C19. and 2E1 activity in vivo. Clin Pharmacol Ther 63: 148
50. Watkins PB, Turgeon DK, Saenger P et al (1992) Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 52: 65-73
51. Cheng CL, Smith DE, Carver PL et al (1997) Steady state pharmacokinetics of delavirdine in HIV positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 61: 531-543